肺癌是世界范圍內(nèi)最常見的呼吸道惡性腫瘤，因其較高的發(fā)病率和致死率，已嚴重危害人類的身心健康。中醫(yī)藥在抗肺癌綜合治療方面應(yīng)用歷史悠久，優(yōu)勢突出，療效良好，而中藥活性成分大多具有良好的抗肺癌作用。研究發(fā)現(xiàn)，一些中藥活性成分可以通過靶向肺癌信號通路，調(diào)節(jié)肺癌腫瘤免疫微環(huán)境中巨噬細胞、自然殺傷細胞、髓系抑制細胞、T細胞、調(diào)節(jié)性T細胞以及樹突狀細胞等免疫細胞，改善肺癌腫瘤免疫微環(huán)境，提高免疫細胞的功能和活性，增強機體免疫功能，逆轉(zhuǎn)機體免疫抑制狀態(tài)，從而發(fā)揮抗肺癌治療的作用。通過收集近年來國內(nèi)外中藥活性成分（淫羊藿多糖、丹參酮Ⅰ、黃芪甲苷、牡荊素、人參皂苷、薯蕷皂苷、姜黃素、丹參酮Ⅱ_A、大黃素、黃芪多糖、紅景天苷、靈芝多糖、白藜蘆醇等）在抗肺癌治療中的相關(guān)研究報道，從中藥活性成分調(diào)節(jié)免疫細胞及其抗肺癌作用具體機制方面進行論述，以期為相關(guān)新型臨床抗肺癌藥物的研發(fā)提供新的理論依據(jù)。

Lung cancer is the most common malignancy of respiratory tract in the world. Due to its high morbidity and mortality, it has seriously harmed human physical and mental health. Chinese materia medica has a long history in the comprehensive treatment of anti-lung cancer, with outstanding advantages and good curative effect, and most of the active ingredients of Chinese materia medica have good anti-lung cancer effects. Studies have found that some active ingredients of Chinese medicine can regulate immune cells such as macrophages, natural killer cells, myelocyte suppressor cells, T cells, regulatory T cells and dendritic cells in the immune microenvironment of lung cancer by targeting lung cancer signaling pathway, improve the immune microenvironment of lung cancer tumor, improve the function and activity of immune cells, and enhance the immune function of the body. Reverse the immune suppression of the body, so as to play the role of anti-lung cancer treatment. In this paper, through collecting the relevant literatures of Chinese materia medica active ingredients (epimedium polysaccharide, tanshinone Ⅰ, astragaloside IV, mongoin, ginsenoside, diosgenin, curcumin, tanshinone Ⅱ_A, rhododendron, astragalus polysaccharide, astragalus polysaccharide, Rhodiola rosea glycosides, Ganoderma lucidum polysaccharides, resveratrol, et al) in anti-lung cancer treatment at home and abroad in recent years, the regulation of immune cells by Chinese materia medica active ingredients and the specific mechanism of their anti-lung cancer effects were discussed, in order to provide a new theoretical basis for the research and development of related new clinical anti-lung cancer drugs.

R285.5

國家自然科學(xué)基金資助項目（82204981）;河南省特色骨干學(xué)科中醫(yī)學(xué)學(xué)科建設(shè)項目（STG-ZYX06-202145）;河南省中醫(yī)藥科學(xué)研究專項課題（2021JDZX2002）;河南省中醫(yī)院博士科研基金項目（2022BSJJ07）;河南省中醫(yī)院博士科研基金項目（2023BSJJ02）;河南省中醫(yī)藥科學(xué)研究專項課題（20-21ZY2115）;河南中醫(yī)藥大學(xué)2022年度研究生科研創(chuàng)新能力提升計劃項目（2022KYCX057）;河南中醫(yī)藥大學(xué)2023年度研究生科研創(chuàng)新能力提升計劃項目（2023KYCX043）;河南中醫(yī)藥大學(xué)2023年度研究生科研創(chuàng)新能力提升計劃項目（2023KYCX051）